Advanced search
Publication Cover
Journal of Medical Economics Volume 19, 2016 - Issue 10
Submit an article Journal homepage
658
Views
7
CrossRef citations to date
0
Altmetric
Hepatology

Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection

Scott J. JohnsonMedicus Economics Inc., Milton, MA, USA;
,
Hélène PariséMedicus Economics Inc., Milton, MA, USA;
,
Suchin VirabhakMedicus Economics Inc., Milton, MA, USA;
,
Ivana FilipovicAbbVie UK, Maidenhead, Berkshire, UK;
,
Jennifer C. SampAbbVie Global, Mettawa, IL, USACorrespondence[email protected]
&
Derek MisurskiAbbVie Global, Mettawa, IL, USA
Pages 983-994 | Received 21 Mar 2016, Accepted 11 May 2016, Published online: 30 May 2016

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Ru Han, Shuyao Liang, Clément François, Samuel Aballea, Emilie Clay & Mondher Toumi. (2021) Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach. Journal of Market Access & Health Policy 9:1.
Read now
Jaume Puig-Junoy, Natàlia Pascual-Argente, Lluc Puig-Codina, Laura Planellas & Míriam Solozabal. (2018) Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review. Expert Review of Gastroenterology & Hepatology 12:12, pages 1251-1263.
Read now

Articles from other publishers (5)

Ru Han, Clément François & Mondher Toumi. (2020) Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results. Applied Health Economics and Health Policy 19:1, pages 29-44.
Crossref
Isao Kawaguchi, Kazuaki Chayama, Yuri Sanchez Gonzalez, Suchin Virabhak, Dominic Mitchell, Cammy Yuen & Hiromitsu Kumada. (2019) A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. Advances in Therapy 37:1, pages 457-476.
Crossref
László Szilberhorn, Zoltán Kaló & Tamás Ágh. (2018) Cost-Effectiveness of Second-generation Direct-acting Antiviral Agents in Chronic HCV Infection: A Systematic Literature Review. Antiviral Therapy 24:4, pages 247-259.
Crossref
Haruki Uojima, Shuzo Kobayashi, Hisashi Hidaka, Takeshi Kinbara, Tomoaki Fujikawa, Tsuyoshi Nakayama, Hiroki Yamanoue, Takayuki Kanemaru, Tohru Hashimotoh, Ji Hyun Sung, Makoto Kako & Wasaburo Koizumi. (2019) Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients. Annals of Hepatology 18:1, pages 109-115.
Crossref
Lauren E. Cipriano & Jeremy D. Goldhaber-Fiebert. (2018) Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy & Practice 3:1, pages 238146831877663.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.